コレラワクチンの世界市場：成長、将来展望、競合分析 (2022年～2030年)

世界のコレラワクチンの市場規模は、各国政府の予防接種プログラムへの取り組み強化と、特にアジア・アフリカの新興国におけるコレラ発生率の上昇により、予測期間中に10%のCAGRで大幅に成長すると予想されています。

製品別ではDukoralが、欧州・カナダ・オーストラリアの旅行者のために利用可能な唯一の承認されたコレラワクチンであるなどのいくつかの要因のために、2021年時点で最大の市場シェアを保有しています。一方でVaxchoraは、政府が18歳から64歳までのコレラ感染地域への渡航者に使用を推奨していること、米国で入手可能な唯一のコレラ予防ワクチンであること、世界各地で認可されている唯一のコレラ用単回投与ワクチンであることから、予測期間中に大きな成長を見せると予想されます。

地域別では、アジア太平洋地域がコレラワクチンの最大市場として観測されました。コレラに罹患する患者数の多さ、医療への関心増大、各国政府の治療・啓発プログラムへの取り組みなどが、市場成長を牽引しています。一方、北米は予測期間中に最も速い成長を示すと予想されています。

当レポートでは、世界のコレラワクチン市場について分析し、市場の基本構造やマクロ的・ミクロ的環境要因、全体的な市場規模の動向見通し (2020年～2030年)、製品別・地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルと成長戦略、といった情報を取りまとめてお届けいたします。

目次

第1章 序論

第2章 エグゼクティブサマリー

第3章 コレラワクチン市場：競合分析

• コレラワクチン市場：主要ベンダーの市場ポジショニング
• コレラワクチン市場のベンダーが採用した戦略
• 主要な業界戦略
• 階層分析 (2021年・2030年)

第4章 コレラワクチン市場：マクロ分析と市場力学

• イントロダクション
• 世界のコレラワクチンの市場規模 (単位：100万米ドル、2020年～2030年)
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進・抑制要因の影響分析
• シーソー分析

第5章 コレラワクチン市場：製品別 (単位：100万米ドル、2020年～2030年)

• 市場概要
• 成長・収益分析 (2021年/2030年)
• 市場区分
  • Dukoral
  • Shanchol
  • Vaxchora
  • その他

第6章 北米のコレラワクチン市場、2020年から2030年、米ドル（百万）

• 市場概要
• コレラワクチン市場：製品別、2020-2030年、米ドル（百万）
• コレラワクチン市場：地域別、2020-2030年、米ドル（百万）
  • 北米

第7章 英国・EU諸国のコレラワクチン市場 (単位：100万米ドル、2020年～2030年)

第8章 アジア太平洋のコレラワクチン市場 (単位：100万米ドル、2020年～2030年)

第9章 ラテンアメリカのコレラワクチン市場 (単位：100万米ドル、2020年～2030年)

第10章 中東・アフリカのコレラワクチン市場 (単位：100万米ドル、2020年～2030年)

第11章 企業プロファイル

• Astellas Pharma, Inc.
• Sonofi
• Emergent BioSolutions, Inc.（PaxVax, Inc.）
• Valneva SE
• Eubiologics Co. Ltd.
• GlaxoSmithKline plc（GSK）
• Merck & Co., Inc.
• Celldex Therapeutics, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceutical Co. Ltd
• Johnson & Johnson（Crucell）

List of Tables

• TABLE 1 Global Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 2 North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 3 U.S. Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 4 Canada Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 5 Rest of North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 6 UK and European Union Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 7 UK Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 8 Germany Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 9 Spain Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 10 Italy Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 11 France Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 12 Rest of Europe Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 13 Asia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 14 China Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 15 Japan Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 16 India Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 17 Australia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 18 South Korea Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 19 Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 20 Brazil Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 21 Mexico Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 22 Rest of Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 23 Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 24 GCC Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 25 Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
• TABLE 26 Rest of Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Cholera Vaccines Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Cholera Vaccines Market: Quality Assurance
• FIG. 5 Global Cholera Vaccines Market, By Product, 2021
• FIG. 6 Global Cholera Vaccines Market, By Geography, 2021
• FIG. 7 Market Geographical Opportunity Matrix - Global Cholera Vaccines Market, 2021
• FIG. 8 Market Positioning of Key Cholera Vaccines Market Players, 2021
• FIG. 9 Global Cholera Vaccines Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
• FIG. 10 Global Cholera Vaccines Market, By Product, 2021 Vs 2030, %
• FIG. 11 U.S. Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 12 Canada Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 13 Rest of North America Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 14 UK Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 15 Germany Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 16 Spain Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 17 Italy Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 18 France Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 19 Rest of Europe Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 20 China Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 21 Japan Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 22 India Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 23 Australia Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 24 South Korea Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 25 Rest of Asia Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 26 Brazil Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 27 Mexico Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 28 Rest of Latin America Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 29 GCC Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 30 Africa Cholera Vaccines Market (US$ Million), 2020 - 2030
• FIG. 31 Rest of Middle East and Africa Cholera Vaccines Market (US$ Million), 2020 - 2030

Global cholera vaccines market is anticipated to grow significantly with a CAGR of 10% during forecast period due to rising government initiatives in immunization program and growing incidence of cholera particularly in developing countries in Asia and Africa would drive the growth of cholera vaccines market globally.

Cholera is an infection of the small intestine by strains of the bacterium Vibrio cholera, which can cause death of the patient if left untreated. According to the World Health Organization (WHO) every year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide; it is affected primarily in Africa, South and Southeast Asia, and South Americas. Some factors such as higher prevalence of cholera in some African and south Asian countries and government initiative in immunization program are prime factors that driving the growth of cholera vaccines market globally. For the purpose of study market is segmented on the basis of product type such as dukoral, shanchol, vaxchora and others vaccines and geography. It is studied that, there are three WHO-prequalified, killed, whole-cell oral cholera vaccines are currently extensively use in market; among these Dukoral was observed as largest revenue contributing segment because it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries and it prevent diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC) are primarily driving the growth of Dukoral market globally.

For the purpose of this study, the global cholera vaccines market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Asia Pacific currently dominates the global cholera vaccines market because large number of affected populations in South-East Asian countries and government initiatives in immunization program are prime factors that driving the market growth in Asia Pacific. However, it is estimated that North America will show the highest growth during forecast period and growth will mainly fuel by a new approved oral vaccine Vaxchora, as it is the only vaccine available in the United States for protection against cholera.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cholera vaccines market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cholera vaccines market. This report concludes with company profiles section that highlights major information about the key players engaged in global cholera vaccines market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

It is studied that in the base year 2021, Dukoral held largest market share, due to some factors such as it is the only approved cholera vaccine available for European, Canadian and Australian travelers, it prevents diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC), it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries are primarily driving the growth of Dukoral market. On the other hand Vaxchora will expected to show significant growth during forecast period due to government recommendation for use in adults 18 through 64 years of age traveling to cholera-affected areas, it is the only vaccine available in the United States for protection against cholera and the only single dose vaccine for cholera currently licensed anywhere in the world these factors would expected to drive the market during forecast period.

Asia Pacific Dominates the market

In the base 2021, Asia Pacific was observed as the largest market for cholera vaccines because large pool of patients suffering with cholera, increasing healthcare awareness, government initiatives in treatment and awareness program are primarily driving the market growth in Asia Pacific. On the other hand North America expected to show fastest growth during forecast period because Vaxchora is the only vaccine available in the United States for protection against cholera and recommended use in adults 18 through 64 years of age traveling to cholera-affected areas would expected to assist the market growth in North America.

According to World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases, and 21,000 to 143,000 deaths per year worldwide. For the purpose of this study, the global cholera market is regionally categorized as North America, Europe, Asia Pacific, LATAM and MEA; among the considered regional markets North America is expected to dominate the cholera market during forecast period due to higher healthcare awareness among general population, government initiatives in treatment and awareness program, higher cost of vaccines and presence of key manufacturer would drive the market growth in North America, recently approved vaxchora would primarily assist market growth in North America. Centers for Disease Control and Prevention (CDC) recommendation for travelers to cholera-affected regions would fuel the market growth in United States. On the other hand, Asia Pacific is currently dominating the Cholera vaccines market due to increasing awareness of immunization, higher number of targeted population and government initiatives in awareness program are primarily driving the market growth in Asia Pacific.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cholera Vaccines market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Cholera Vaccines market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

Dukoral

Shanchol

Vaxchora

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Cholera Vaccines market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Cholera Vaccines market?

Which is the largest regional market for Cholera Vaccines market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Cholera Vaccines market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Cholera Vaccines market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Cholera Vaccines Market
• 2.2. Global Cholera Vaccines Market, By Product, 2021 (US$ Million)
• 2.3. Global Cholera Vaccines Market, By Geography, 2021 (US$ Million)
• 2.4. Attractive Investment Proposition by Geography, 2021

3. Cholera Vaccines Market: Competitive Analysis

• 3.1. Market Positioning of Key Cholera Vaccines Market Vendors
• 3.2. Strategies Adopted by Cholera Vaccines Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2021 Versus 2030

4. Cholera Vaccines Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Cholera Vaccines Market Value, 2020 - 2030, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2021 Versus 2030
• 5.3. Market Segmentation
  • 5.3.1. Dukoral
  • 5.3.2. Shanchol
  • 5.3.3. Vaxchora
  • 5.3.4. Others

6. North America Cholera Vaccines Market, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
• 6.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
  • 6.3.1.North America
    • 6.3.1.1. U.S.
      • 6.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 6.3.1.2. Canada
      • 6.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 6.3.1.3. Rest of North America
      • 6.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

7. UK and European Union Cholera Vaccines Market, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
• 7.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
  • 7.3.1.UK and European Union
    • 7.3.1.1. UK
      • 7.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 7.3.1.2. Germany
      • 7.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 7.3.1.3. Spain
      • 7.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 7.3.1.4. Italy
      • 7.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 7.3.1.5. France
      • 7.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 7.3.1.6. Rest of Europe
      • 7.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

8. Asia Pacific Cholera Vaccines Market, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
• 8.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
  • 8.3.1.Asia Pacific
    • 8.3.1.1. China
      • 8.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 8.3.1.2. Japan
      • 8.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 8.3.1.3. India
      • 8.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 8.3.1.4. Australia
      • 8.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 8.3.1.5. South Korea
      • 8.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 8.3.1.6. Rest of Asia Pacific
      • 8.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

9. Latin America Cholera Vaccines Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
• 9.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
  • 9.3.1.Latin America
    • 9.3.1.1. Brazil
      • 9.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 9.3.1.2. Mexico
      • 9.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 9.3.1.3. Rest of Latin America
      • 9.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

10. Middle East and Africa Cholera Vaccines Market, 2020-2030, USD (Million)

• 10.1. Market Overview
• 10.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
• 10.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
  • 10.3.1.Middle East and Africa
    • 10.3.1.1. GCC
      • 10.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 10.3.1.2. Africa
      • 10.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
    • 10.3.1.3. Rest of Middle East and Africa
      • 10.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

11. Company Profile

• 11.1. Astellas Pharma, Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Portfolio
  • 11.1.4. Strategic Initiatives
• 11.2. Sonofi
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Portfolio
  • 11.2.4. Strategic Initiatives
• 11.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Portfolio
  • 11.3.4. Strategic Initiatives
• 11.4. Valneva SE
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Portfolio
  • 11.4.4. Strategic Initiatives
• 11.5. Eubiologics Co. Ltd.
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Portfolio
  • 11.5.4. Strategic Initiatives
• 11.6. GlaxoSmithKline plc (GSK)
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Portfolio
  • 11.6.4. Strategic Initiatives
• 11.7. Merck & Co., Inc.
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Portfolio
  • 11.7.4. Strategic Initiatives
• 11.8. Celldex Therapeutics, Inc.
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Portfolio
  • 11.8.4. Strategic Initiatives
• 11.9. Mitsubishi Tanabe Pharma Corporation
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Portfolio
  • 11.9.4. Strategic Initiatives
• 11.10. Takeda Pharmaceutical Co. Ltd
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Portfolio
  • 11.10.4. Strategic Initiatives
• 11.11. Johnson & Johnson (Crucell)
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Portfolio
  • 11.11.4. Strategic Initiatives